Vipergen

Overview

Vipergen specializes in DNA-encoded library (DEL) screening services for accelerating hit identification in early-stage drug discovery. The company has been focused on DNA-encoded library synthesis and screening since 2005.

Core Services

Vipergen offers flexible DEL screening packages:

• DEL Snap: Fast, affordable early lead identification for startups (20 business days; requires biotinylated protein)
• DEL Express: Hit list and structures for tractable targets with purified protein (20 business days)
• DELs in Cells Snap: Early lead discovery using amino acid sequence input (40 business days)
• DELs in Cells Express: Hit identification without purified protein requirement (30 business days)
• Custom DEL Screen: Bespoke campaigns for difficult targets including molecular glues, protein-protein interactions, transcription factors, and membrane proteins
• Custom DEL in Cells Screen: In-cell screening for challenging targets

Key Differentiators

• High-fidelity libraries (yoctoReactor): Constructed without truncates and with 100% barcode-to-compound correspondence, improving hit validation rates
• Massive chemical space: Each library contains 500+ million drug-like molecules screened in single experiments
• Multiple screening formats: Binder Trap Enrichment (BTE) for homogeneous in vitro selections and cellular BTE (cBTE) for screening inside living cells
• Reduced barriers to entry: cBTE eliminates the need for highly purified target protein and broadens accessible target space
• Actionable outputs: Ranked hits with chemical structures and data designed to accelerate medicinal chemistry decisions

Commercial Models

Vipergen offers flexible engagement structures:

• Fee-for-Service (standard): DEL screening with optional off-DNA resynthesis
• Collaborative models: Extended hit-to-lead partnerships where appropriate

IP & Ownership

• Client owns program-specific data and validated compounds generated for their target
• Vipergen retains background IP related to platform technologies, library design, and methods
• Client owns foreground IP for nominated chemical series with no downstream financial obligations